- Home
- CNTX vs GALT Comparison
CNTX vs GALT Comparison
Compare CNTX & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- GALT
- Stock Information
- Founded
- CNTX 2015
- GALT 2000
- Country
- CNTX United States
- GALT United States
- Employees
- CNTX N/A
- GALT N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- GALT Health Care
- Exchange
- CNTX Nasdaq
- GALT Nasdaq
- Market Cap
- CNTX 78.0M
- GALT 83.5M
- IPO Year
- CNTX 2021
- GALT N/A
- Fundamental
- Price
- CNTX $0.63
- GALT $2.18
- Analyst Decision
- CNTX Strong Buy
- GALT Buy
- Analyst Count
- CNTX 5
- GALT 2
- Target Price
- CNTX $5.50
- GALT $6.00
- AVG Volume (30 Days)
- CNTX 324.1K
- GALT 1.4M
- Earning Date
- CNTX 08-06-2025
- GALT 08-12-2025
- Dividend Yield
- CNTX N/A
- GALT N/A
- EPS Growth
- CNTX N/A
- GALT N/A
- EPS
- CNTX N/A
- GALT N/A
- Revenue
- CNTX N/A
- GALT N/A
- Revenue This Year
- CNTX N/A
- GALT N/A
- Revenue Next Year
- CNTX N/A
- GALT N/A
- P/E Ratio
- CNTX N/A
- GALT N/A
- Revenue Growth
- CNTX N/A
- GALT N/A
- 52 Week Low
- CNTX $0.49
- GALT $0.73
- 52 Week High
- CNTX $2.75
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- CNTX 50.76
- GALT 57.57
- Support Level
- CNTX $0.62
- GALT $2.21
- Resistance Level
- CNTX $0.70
- GALT $2.66
- Average True Range (ATR)
- CNTX 0.05
- GALT 0.52
- MACD
- CNTX 0.01
- GALT 0.01
- Stochastic Oscillator
- CNTX 56.44
- GALT 35.52
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.